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Scientific Opinion 
Scientific Opinion on Flavouring Group Evaluation 205 (FGE.205): 
Consideration of genotoxicity data on representatives for 13 α,β-
unsaturated aliphatic ketones with terminal double bonds and precursors 
from chemical subgroup 1.2.2 of FGE.19 by EFSA1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider in the Flavouring Group Evaluation 205, the additional data on genotoxicity 
submitted by the Industry on two representative substances, oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one 
[FL-no: 07.102], from subgroup 1.2.2 of FGE.19. The Panel concluded that both substances were weakly 
genotoxic in bacteria with pent-1-en-3-one being the most potent (previously available data). In these assays the 
representative substances were highly cytotoxic with a steep toxicity curve, and with a very narrow 
concentration range resulting in mutagenicity. Both substances were also tested in mammalian cells for gene 
mutations at the hprt locus and for structural and numerical chromosomal aberrations in the micronucleus assay. 
Also in mammalian cells the test substances were highly cytotoxic. The Panel considered that the positive 
effects in the bacterial mutagenicity assays of the two representative substances cannot be overruled by the one 
negative and one equivocal gene mutation test in mammalian cells and the Panel recommend that an in vivo 
Comet assay on the first site of contact (e.g. the stomach) and on the liver is requested on the most potent of the 
representative substances, pent-1-en-3-one.  
© European Food Safety Authority, 2012 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate flavouring substances using the 
Procedure as referred to in the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation 205 (FGE.205), corresponding to subgroup 1.2.2 of 
FGE.19, concerns four α,β-unsaturated aliphatic ketones with a terminal double-bond and nine 
precursors for such ketones. The 13 substances under consideration in the present evaluation are α,β-
unsaturated ketone structures or can be metabolised to such, which are considered to be structural 
alerts for genotoxicity and the data on genotoxicity previously available did not rule out the concern 
for genotoxicity. The Panel has identified two substances in subgroup 1.2.2, oct-1-en-3-one [FL-no: 
07.081] and pent-1-en-3-one [FL-no: 07.102], which will represent the other 11 substances in this 
subgroup. For these two substances, genotoxicity data according to the test strategy worked out by the 
Panel have been requested. 
The Industry has subsequently submitted data concerning genotoxicity studies for the two 
representative substances of subgroup 1.2.2. 
According to these data, both oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one [FL-no: 07.102] 
were mutagenic in bacteria and highly cytotoxic with a steep toxicity curve, and with a very narrow 
concentration range resulting in mutagenicity. Both substances were also tested in mammalian cells 
for gene mutations at the hprt locus and for structural and numerical chromosomal aberrations in the 
micronucleus assay. Also in mammalian cells the test substances were highly cytotoxic. The Panel 
considered that the positive effects in the bacterial mutagenicity assays of the two representative 
substances cannot be overruled by the one negative and one equivocal gene mutation test in 
mammalian cells and the Panel recommends that an in vivo Comet assay on the first site of contact 
(e.g. the stomach) and on the liver is requested on the most potent of the representative substances, 
pent-1-en-3-one. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union list of flavouring substances for use in or 
on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008b). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008b). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models, internal and external validation has been performed, 
but considered that the outcome of these validations was not always extensive enough to appreciate 
the validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008b) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established, 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225). 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
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Procedure. For all or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA has worked out a list of 
representative substances for each subgroup (EFSA, 2008bc). Likewise an EFSA genotoxicity expert 
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 
2008bb). 
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup.   
The Flavouring Industry has now submitted additional data and the present FGE concerns the 
evaluation of these data requested on genotoxicity. 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following 13 substances: oct-l-en-3-ol [FL-no: 02.023], pent-1-en-3-ol [FL-no: 
02.099], hex-l-en-3-ol [FL-no: 02.104], but-3-en-2-ol [FL-no: 02.131], dec-l-en-3-ol [FL-no: 02.136], 
l-hepten-3-ol [FL-no: 02.155], non-l-en-3-ol [FL-no: 02.187], oct-l-en-3-one [FL-no: 07.081], pent-l-
en-3-one [FL-no: 07.102], hex-l-en-3-one [FL-no: 07.161], l-nonene-3-one [FL-no: 07.210], oct-l-en-
3-yl acetate [FL-no: 09.281] and oct-l-en-3-yl butyrate [FL-no: 09.282], in accordance with 
Commission Regulation (EC) N° 1565/2000. 
ASSESSMENT 
1. Presentation of the substances in the Flavouring Group 
1.1. Description 
The present Flavouring Group Evaluation 205 (FGE.205), corresponding to subgroup 1.2.2 of FGE.19, 
concerns four α,β-unsaturated aliphatic ketones with a terminal double-bond and nine precursors for 
such ketones. The 13 substances under consideration in the present evaluation are listed in Table 1.  
Nine of the 13 substances have previously been evaluated by the JECFA at their 59th and 69th meetings 
(JECFA, 2002c; JECFA, 2009c). A summary of their current evaluation status by the JECFA and the 
outcome of this consideration is presented in Table 2. 
The α,β-unsaturated aldehyde and ketone structures are considered to be structural alerts for 
genotoxicity (EFSA, 2008b) and the data on genotoxicity previously available did not rule out the 
concern for genotoxicity. 
1.2. Representative substances for subgroup 1.2.2 
The Panel has identified two substances in subgroup 1.2.2 which will represent the other 11 substances 
in this subgroup (EFSA, 2008bc). For these two substances genotoxicity data according to the test 
strategy (EFSA, 2008bb) have been requested. The representative substances are listed in Table 1.2. 
Table 1.2 Representative substances for subgroup 1.2.2 of FGE.19  
FL-no  
JECFA-
no  
Subgrou
p  
EU Register name  Structural formula  FEMA no  
CoE no  
CAS no  
07.081  
1148  
1.2.2  Oct-1-en-3-one 
  
3515  
2312  
4312-99-6 
O
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Table 1.2 Representative substances for subgroup 1.2.2 of FGE.19  
FL-no  
JECFA-
no  
Subgrou
p  
EU Register name  Structural formula  FEMA no  
CoE no  
CAS no  
07.102  
1147 
1.2.2  Pent-1-en-3-one 
 
3382  
11179  
1629-58-9 
 
2. Additionally submitted genotoxicity data on representative substances of subgroup 1.2.2 
The Industry has submitted data concerning genotoxicity studies (EFFA, 2011p) for the two 
representative substances for this subgroup: 
• Oct-1-en-3-one (amyl vinyl ketone) [FL-no: 07.081]. 
• Pent-1-en-3-one (ethyl vinyl ketone) [FL-no: 07.102]. 
2.1. In vitro data 
An Ames test, a hprt assay and an in vitro micronucleus assay has been performed with oct-1-en-3-one 
[FL-no: 07.081].  An in vitro micronucleus assay and a hprt assay has been performed with pent-1-en-
3-one [FL-no: 07.102]. Besides these new studies submitted by Industry, some older studies already 
considered by the Panel (EFSA, 2008b) with pent-1-en-3-one were included in the submission. An 
overview of the studies are summarised in Table 3.   
2.1.1. Oct-1-en-3-one (amyl vinyl ketone) [FL-no: 07.081] 
2.1.1.1.  Genotoxicity in bacteria 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 to assess the mutagenicity of oct-1-en-3-one, both in the absence and in the presence of 
metabolic activation by S9-mix, in three experiments. An initial toxicity range-finding experiment was 
carried out in the absence and presence of S9-mix in strain TA100 only, using final concentrations of 
oct-1-en-3-one at 1.6, 8, 40, 200, 1000 and 5000 μg/plate, plus negative (solvent) and positive 
controls. Evidence of toxicity was apparent on all plates treated at 200 μg/plate and above in the 
absence and in the presence of S9-mix. Based on this toxicity data the following concentrations were 
used for all tester strains in the first experiment:  0.32, 1.6, 8, 40, 200 and 1000 μg/plate. Following 
these treatments, evidence of toxicity was observed in all strains at concentrations of 200 and/or 1000 
μg/plate, both in the absence and in the presence of S9-mix. Negative results were obtained for all 
strains with and without S9-mix, except for TA100 with S9-mix, where a statistically significant 
increase in the number of revertants above the control was observed at 40 μg/plate, where the number 
of revertants increased 1.2-fold and at 200 μg/plate with an increase of 4.6-fold. Toxicity was 
observed at 1000 μg/plate (Beevers, 2009c). 
In the second experiment, plate-incorporation treatments of all the tester strains were performed in the 
absence of S9-mix, with the maximum test concentration reduced to 500 μg/plate to account for a 
revised estimate of the toxicity limit. In addition, all treatments in the presence of S9-mix were further 
modified by the inclusion of a pre-incubation step to increase the range of mutagenic detection. 
Following these treatments, evidence of toxicity was observed in all strains at concentrations of 125 or 
250 μg/plate and above in the absence of S9-mix and at 62.5 μg/plate and above in the presence of S9-
mix. No statistically significant increases in the number of revertants were seen in any strain, except 
TA100. Without S9-mix the number of revertants in strain TA100 increased 1.2 and 1.4-fold at 62.5 
and 125 μg/plate, respectively, and with S9-mix treatment a 1.2-fold increase was observed at 31.25 
μg/plate. These increases are below the threshold that is normally considered biologically relevant, 
which is a 2-fold increase threshold. In addition to the pre-incubation treatments described above (with 
O
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S9-mix), plate incorporation treatments of strain TA100 in the presence of S9-mix were performed at 
50, 100, 200, 300, 400 and 500 μg/plate. Evidence of toxicity was observed on all plates treated at 300 
μg/plate and above, but there were no statistically significant increases in revertant numbers at any 
concentration. 
In the third experiment, only the TA100 strain was evaluated since it was weakly positive in the 
previous experiments. Plate-incorporation treatments in the absence and presence of S9-mix were 
performed at 100, 125, 150, 175, 200, 225, 250 and 300 μg/plate. Pre-incubation treatments solely in 
the presence of S9-mix were performed at 15, 30, 45, 60, 75, 90 105 and 120 μg/plate. Following these 
treatments, evidence of toxicity was observed at 225 or 250 μg/plate and above (plate-incorporation 
treatments in the absence or presence of S9-mix, respectively) and at 60 μg/plate (pre-incubation 
treatments). The plate-incorporation method resulted in increased revertants by 2.3 to 3-fold at 
treatment concentrations of 125 - 200 μg/plate in the absence of S9-mix, and 2.2 to 2.9-fold at 
treatment concentrations of 100 - 200 μg/plate in the presence of S9-mix. In both cases the increases 
were not concentration-related. Using pre-incubation methodology, a 1.7-fold increase in revertants 
was observed at 45 μg/plate treatments in the presence of S9-mix. 
Overall, small but statistically significant (Dunnett’s test, 1 % level) increases in revertant numbers 
were observed following oct-1-en-3-one treatments of strain TA100 both in the absence and in the 
presence of metabolic activation by S9-mix. This weak mutagenic response was not reproduced on 
every experimental occasion, but where significant increases were observed, they were small in 
magnitude and limited by toxicity at the next highest oct-1-en-3-one concentrations. The lack of 
consistent reproducibility of this weak mutagenic response was attributed to variation in toxicity 
among experiments, and to a small window where mutagenic responses could be observed. 
The Panel concluded that oct-1-en-3-one is a weak inducer of mutations in the TA100 strain of S. 
typhimurium when tested up to toxic concentrations in the absence and in the presence of a rat liver 
metabolic activation system. 
2.1.1.2. hprt assays 
In light of the weak positive result in the Ames test it was deemed relevant by the applicant to assess 
oct-1-en-3-one for its ability to induce mutation at the hprt locus in mouse lymphoma cells. The study 
consisted of two cytotoxicity range-finding experiments followed by three separate experiments. Two 
were conducted for 3 hours in the absence and presence of metabolic activation by an Aroclor 1254 
induced rat liver post-mitochondrial fraction (S9-mix), followed by a third experiment conducted for 
24 hours in the absence of S9-mix. In the cytotoxicity range-finding experiment using a 3-hour 
treatment, ten concentrations were tested in the absence and presence of S9-mix, ranging from 2.5 to 
1262 μg/mL (10 mM). The highest concentrations not resulting in severe cotytoxicity were 2.5 μg/mL 
in the absence of S9-mix and 4.9 μg/mL in the presence of S9-mix, which gave 2 % and 9 % relative 
survival (RS), respectively. In the cytotoxicity range-finding experiment using 24-hour treatments, 
nine concentrations were tested in the absence of S9-mix, ranging from 0.01 to 3 μg/mL. The highest 
concentration to provide > 10 % RS was 1.5 μg/mL, which gave 22 % RS. Based on this range finding 
study, twelve concentrations from 0.05 to 2.5 μg/mL in the absence of S9-mix, and from 0.5 to 7.5 
μg/mL in the presence of S9-mix, were tested in the first mutation experiment using 3-hour treatments, 
and 7 days recovery period. The  highest non-toxic concentrations were 2 μg/mL in the absence of S9-
mix and 3 μg/mL in the presence of S9-mix, which gave 12 % and 19 % RS, respectively. In the 
absence of S9-mix, a statistically significant increase in mutant frequency (MF; 4.23 mutants per 106 
viable cells compared to the mean vehicle control MF of 1.10 mutants per 106 viable cells) was 
observed at the highest concentration (2 μg/mL), but there was no statistically significant linear trend 
(Lloyd, 2011c).  
In the second experiment using 3-hour treatments, ten concentrations ranging from 0.5 to 3 μg/mL in 
the absence of S9-mix, and from 0.5 to 4.5 μg/mL in the presence of S9-mix, were tested. Since the 
highest concentration evaluated in the first experiment (2 μg/mL) resulted in a relative survival < 10 
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%, the highest concentration evaluated in the second experiment was 1.8 μg/mL in the absence of S9-
mix (11 % RS) and 4.5 μg/mL in the presence of S9-mix (24 % RS). There were no statistically 
significant increases in MF at any concentration analyzed or linear trends. The small increase in MF 
observed in the first experiment was therefore not reproduced (Lloyd, 2011c). 
In the third experiment using 24-hour treatment in the absence of S9-mix, eleven concentrations 
ranging from 0.1 to 2.5 μg/mL were tested. Seven days after treatment the highest concentration not 
too toxic for selection (1.2 μg/mL) resulted in 16 % RS. Mutant frequencies in all treated cultures were 
lower than in the concurrent control (Lloyd, 2011c). 
In this study high cytototoxicity was observed, which complicates the evaluation of oct-1-en-3-one for  
genotoxicity in mammalian cells. Some indication of genotoxicity was observed in the absence of S9-
mix at the highest non-toxic concentration tested (2 μg/mL) and 3 hours treatment, which however 
could not be reproduced in the second experiment using the same treatment conditions and a third 
experiment using 24 hours treatment. It is therefore concluded, that this gene mutation test is negative 
under the experimental conditions performed. 
2.1.1.3. In vitro micronucleus assays 
Oct-1-en-3-one was tested in an in vitro micronucleus assay using duplicate human lymphocyte 
cultures prepared from the pooled blood of two female donors both in the absence and presence of 
metabolic activation (S9-mix).  
After stimulation for 48 hours with phytohaemagglutinin (PHA) cells were treated with oct-1-en-3-one 
for 3 hours (followed by 21 hours recovery) with and without S9-mix and for 24 hours without S9-
mix. An initial range-finding experiment using 4.6 - 1262 μg/mL oct-1-en-3-one (i.e. up to 10 mM) 
was performed. Based on the cytotoxicity data obtained in this study, measured by effect on the 
replication index (RI), concentrations ranging from 2 - 20 μg/mL (absence of S9-mix) or 5 - 40 μg/mL 
(presence of S9-mix) were chosen for the main experiment with 3-hour treatments. The 3+21 hours 
treatment in the absence of S9-mix resulted in 81 - 99 % toxicity at 10 μg/mL and above. 
Concentrations of 2, 4, and 8 μg/mL resulted in 0.20 - 0.35 % MNBN cell frequency which was below 
that of the concurrent control. The 3+21 hours treatment in the presence of S9-mix resulted in 81 % 
cytotoxcicity or greater at concentrations of 20 μg/mL and above. Five, 10 and 15 μg/mL treatments 
resulted in MNBN cell frequencies (0.3 - 0.55 %) similar to that of the control (0.5 %) (Lloyd, 2011b). 
Since the 3-hour treatments produced negative results for micronucleus (MN) induction, treatments 
were also performed over a 24-hour period in the absence of S9. In the range-finding experiment 
concentrations again ranged up to 1262 μg/mL (10 mM) but cells did not replicate (zero RI) at 
concentrations of 35.33 μg/ml and above. Also there was 94 % toxicity at 12 μg/mL. Therefore, 10 
μg/mL was chosen as the top concentration for evaluation (range of tested concentrations are tabulated 
in Table 3), where RI was reduced by 62 %. Treatment at this concentration resulted in a statistically 
significant (p < 0.01) increase in mean MNBN (micronucleated binucleated cells) cell frequency to 
1.65 % (concurrent control was 0.65 %). However, the MNBN frequency only exceeded the normal 
range in 1 of the 2 replicate cultures, and there was no increase in MNBN frequency at 8 μg/mL where 
reduction in RI was 58 %, or any of the lower concentrations. Given that the only positive response 
was in 1 replicate at toxicity exceeding 60 %, and that at the recommended range toxicity (58 %) there 
was no increase in MN frequency, this is considered to be an indirect consequence of high levels of 
toxicity and is not considered a biologically relevant positive response.  
Taken as a whole, treatment with oct-1-en-3-one at acceptable levels of toxicity resulted in frequencies 
of MNBN cells that were generally similar to (and not significantly different from) those observed in 
concurrent vehicle controls. It was concluded that oct-1-en-3-one did not induce micronuclei in 
cultured human peripheral blood lymphocytes when tested up to toxic concentrations for 3+21 hours 
in the absence and presence of S9-mix and for 24+0 hours in the absence of S9-mix (Lloyd, 2011b). 
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2.1.2. Pent-1-en-3-one (ethyl vinyl ketone) [FL-no: 07.102] 
2.1.2.1. Genotoxicity in bacteria 
Previously available in vitro data 
In a study by Deininger et al. (Deininger et al., 1990), ethyl vinyl ketone (EVK) was tested for the 
induction of gene mutations in S. thyphimurium strain TA100 both with and without Aroclor induced 
rat liver S9-mix. The pre-incubation method was used. The substance, dissolved in DMSO, was tested 
up to 2 µmol/plate. In the absence of S9-mix toxicity was observed at a concentration of 0.6 
µmol/plate while no toxicity was observed with S9-mix up to the highest tested concentration.  Ethyl 
vinyl ketone was clearly genotoxic both with and without S9-mix. The specific mutagenicity, 
calculated as the linear slope of the dose response curve, was 1293 revertants per µmol without S9-
mix and 748 revertants per µmol with S9-mix. Though the peak revertant rate was higher with S9-mix 
(1250 revertants at about 2 µmol/plate) than without S9-mix (675 revertants at 0.5 µmol/plate), the 
specific mutagenicity was higher in the absence of S9-mix. This indicates that the effect of S9-mix is 
detoxification. However, in supplementary studies with the enzyme inhibitor SKF 525 (an inhibitor of 
monooxygenase) the mutagenic response disappeared completely, whereas an addition of TCPO (an 
inhibitor of epoxide hydrolase) resulted in an increase of mutagenic activity, indicating that 
epoxidation of the double bond by S9-mix could also play a role in the mutagenicity of EVK. This 
data was also included in a paper from the same research group together with data for other α,β-
unsaturated ketones and aldehydes (Eder et al., 1993). The same study group also isolated and 
characterized guanine and deoxyguanosin adducts with EVK, indicating that EVK can form DNA 
adducts, which can give rise to mutations (Eder et al., 1991a; Eder et al., 1993). The mutagenic effect 
in S. typhimurium TA100 was supported by genotoxicity in the SOS Chromotest performed with the 
Escherichia coli strain PQ37 both with and without S9-mix. Genotoxicity was only observed in the 
presence of S9-mix. The maximum induction factor was 1.83 which is above the limit of 1.5 for a 
positive response. (Deininger et al., 1990; Eder et al., 1991a; Eder et al., 1993). Ethyl vinyl ketone was 
more genotoxic in the SOS Chromotest than methyl vinyl keton (Eder et al., 1993). 
Based on these studies it was concluded that pent-1-en-3-one is genotoxic in bacteria. 
New available in vitro data 
Because of the previously reported positive Ames test with pent-1-en-3-one (Deininger et al., 1990) a 
mammalian cell gene mutation test was performed in mouse lymphoma L5178Y cells and evaluated 
for induction of forward mutations at the hypoxanthine-guanine phosphoribosyl transferase (hprt) 
locus. 
2.1.2.2. hprt assays 
Induction of forward mutations at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus 
after treatment with pent-1-en-3-one in the absence and presence of S9-mix was evaluated. 
Concentrations for the main experiment were established by a preliminary range-finding cytotoxicity 
experiment. In the first mutation experiment cell cultures treated with pent-1-en-3-one for 3 hours at 
0.6, 0.7, 0.8, 0.85, 0.95 and 1.0 μg/ml in the absence of S9-mix and at 1.5, 2, 2.5, 3, 3.25, 3.5, 3.75, 4, 
4.5 and 5 μg/ml in the presence of S9-mix were evaluated (range of tested concentrations are tabulated 
in Table 3). Percent relative survival (% RS) decreased to 16 % and 19 % at the highest concentrations 
of 0.95 and 1.0 μg/ml treatment without S9-mix, respectively. No significant increases in mutant 
frequency were observed at any concentration in the absence of S9-mix. In the presence of S9-mix, the 
highest concentration, 5 μg/ml, resulted in 21 % RS. One statistically significant (Dunnett’s test, 5 % 
level) increase in mutant frequency from the control (2.48 mutants per 106 viable cells) was observed 
at the second highest concentration, 4.5 μg/ml, (8.7 mutants per 106 viable cells) in the presence of S9-
mix in both cultures. A statistically significant linear trend was also observed, although the mutant 
frequency value at the highest concentration tested (5 μg/ml) was not significantly different from the 
solvent control (5.42 mutants per 106 viable cells) (Lloyd, 2011a).  
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Thus, additional experiments were undertaken evaluating mutant frequency after (again) 3-hour 
treatment with pent-1-en-3-one in the presence of S9-mix but also after 24-hour treatment in the 
absence of S9-mix (2 separate experiments). In the presence of S9-mix, the highest concentration 
evaluated (7 μg/ml) reduced RS to 8 %, and therefore exceeded the required level of toxicity. There 
were no statistically significant increases in mutant frequency at any concentration analyzed and no 
statistically significant linear trend. Cultures treated at 4.5 μg/mL gave a 41 % RS, compared to a 36 
% RS in first experiment and did not result in increased mutation frequency. The significant increase 
in mutation frequency observed at a single concentration in the first experiment was not reproduced in 
the second experiment under the same treatment conditions even at higher and more toxic 
concentrations (the maximum concentrations analyzed were 5 and 7 μg/mL in the first and second 
experiments, respectively). Following 24-hour treatments in the absence of S9-mix the top 
concentrations evaluated (1.0 and 0.8 μg/ml in the 2 separate experiments) reduced RS to 12 % in each 
case, and therefore achieved the required level of toxicity for a robust test (range of tested 
concentrations are tabulated in Table 3). There were no statistically significant increases in mutant 
frequency at any concentration and no significant linear trend in either of the two 24-hour 
experiments. The Panel noted that in this in vitro assay pent-1-en-3-one is also cytotoxic to mouse 
lymphoma L5178Y cells which could mask a genotoxic effect. Also, in this hprt assay there was some 
indication of genotoxicity at the second highest concentration and a linear trend in the presence of S9-
mix after 3 hours treatment. Although, this positive effect was not reproduced in a second experiment 
using the same experimental design and a third experiment using 24 hours treatment without S9-mix, 
it was concluded by the Panel that the results in this in vitro gene mutation test is equivocal (Lloyd, 
2011a). 
2.1.2.3. In vitro micronucleus assays 
Pent-1-en-3-one was assayed for the induction of structural and numerical chromosomal aberrations in 
mammalian cells in vitro by examining the effect on the frequency of micronuclei in cultured human 
peripheral blood lymphocytes pooled from 2 healthy male donors both in the absence and presence of 
Aroclor induced rat liver S9-mix. After stimulation with PHA for 48 hours cells were treated with 
pent-1-en-3-one either for 3 hours (followed by 21 hours of recovery) in the absence or presence of 
S9-mix, or for 24 hours in the absence of S9-mix. A range-finding experiment had been conducted 
with and without S9-mix at 12 concentrations up to 841.2 μg/ml (10 mM). In the main assay, 
micronuclei were analyzed at three concentrations for each treatment group. For 3-hour treatment 
without S9-mix the concentrations were 3.5, 4.25 and 4.75 μg/ml, for 3-hour treatment with S9-mix 
the concentrations were 8.0, 12.0 and 16.0 μg/ml, and for 24-hour treatment without S9-mix the 
concentrations were 3.0, 3.5 and 4.0 μg/ml. The levels of cytotoxicity (reduction in replication index, 
RI) analysed for micronucleus at the top concentrations reached 48 and 50 % in the 3-hour treatment 
in the presence of S9-mix and the 24-hour treatment in the absence of S9-mix respectively. Following 
a 3-hour treatment in the absence of S9-mix, toxicity at the highest concentration (4.75 μg/ml) was 
only 38 %. However, the toxicity curve was very steep and at the next higher concentration (5.0 
μg/ml) toxicity was excessive (81 % reduction in RI). One thousand binucleate cells per culture from 2 
(or in some cases 4) replicate cultures per concentration were scored for micronuclei.  
Following the 3-hour treatment without S9-mix, there was an increase in the frequency of 
micronucleated binucleate cells (MNBN) from 0.2 % in the solvent control to 0.55 % at the lowest 
concentration. This increase was statistically significant at p < 0.05 but fell well within the historical 
control range and was therefore not considered to be biologically significant. There were no 
significant increases in MNBN frequency at the middle and high concentrations, and therefore no 
concentration related response. In the presence of S9-mix there were no statistically significant 
increases in mean MNBN cell frequency at any concentration. Following the 24-hour treatment 
without S9-mix a statistically significant (p < 0.01) increase in MNBN cell frequency from 0.40 % in 
the control to 1.1 % was observed at the maximum concentration of 4.0 μg/ml. This elevated 
frequency, which only just exceeded the historical control range for the laboratory (0 - 1.0 %), was due 
entirely to an increase in MNBN frequency in only 1 of the 2 replicate cultures (the other replicate had 
a background MNBN frequency at a comparable level of toxicity), and the overall responses were not 
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clearly concentration-related. Thus, it seems most likely that the single replicate increase was due to 
chance. Treatment of the cells with pent-1-en-3-one under all conditions therefore resulted in 
frequencies of MNBN cells that were generally similar to those observed in concurrent and historical 
vehicle controls at all concentrations analysed (Lloyd, 2010b). It was concluded by the applicant that 
pent-1-en-3-one did not induce micronuclei in cultured human peripheral blood lymphocytes when 
tested at toxic concentrations in both the absence and presence of S9-mix (Lloyd, 2010b). 
The Panel noted that pent-1-en-3-one is extremely cytoxic to human lymphocytes, with a very steep 
toxicity curve and therefore the substance can only be tested for genotoxicity in a narrow 
concentration range.  
A summary of the in vitro genotoxicity date are given in Table 3. 
2.2. In vivo data 
No data submitted 
3. Conclusion by the CEF Panel 
The two representative substances oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one [FL-no: 
07.102] were both weakly genotoxic in bacteria with pent-1-en-3-one being the most potent 
(previously available data). In newly available data performed according to recent guidelines and 
GLP, several studies were performed on oct-1-en-3-one in bacteria. In these assays the test substance 
was highly cytotoxic with a steep toxicity curve, and there was a lack of reproducibility in the weak 
genotoxic response, which could be due to a slight day to day variation of the severity of the observed 
toxicity and a very narrow concentration range resulting in mutagenicity. Both substances were also 
tested in mammalian cells for gene mutations at the hprt locus and for structural and numerical 
chromosomal aberrations in the micronucleus assay. Also in mammalian cells the test substances were 
highly cytotoxic. All the in vitro assays were well performed and each of the assays performed in 
mammalian cells were considered to be negative when looking at them separately, except the gene 
mutation assay with pent-1-en-3-one which was considered by the Panel to be equivocal, presumably 
due to severe cytotoxicity of the test compound. Due to positive effects in the bacterial mutagenicity 
assays of the two representative substances, which cannot be overruled by one negative and one 
equivocal gene mutation test in mammalian cells, an in vivo Comet assay on the first site of contact 
(e.g. the stomach or duodenum) and on the liver is requested on the most potent substance, pent-1-en-
3-one. As an alternative, a transgenic animal assay would also be acceptable. 
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SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 205 (JECFA, 2002D; JECFA, 2009B)  
Table 1:  Specification Summary of the Substances in the present group 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
4) 
Spec.gravity 5) 
02.023 
1152 
Oct-1-en-3-ol   6) 
 
2805 
72 
3391-86-4 
Liquid 
C8H16O 
128.22 
Insoluble 
Miscible 
175-175.2 
 
NMR 
96 % 
1.431-1.442 
0.835-0.845 
02.099 
1150 
Pent-1-en-3-ol   6) 
 
3584 
11717 
616-25-1 
Liquid 
C5H10O 
86.13 
Sparsely soluble 
Miscible 
114 
 
NMR 
98 % 
1.419-1.427 
0.831-0.837 
02.104 
1151 
Hex-1-en-3-ol   6) 
 
3608 
10220 
4798-44-1 
Liquid 
C6H12O 
100.16 
Insoluble 
Miscible 
133.5-134 
 
NMR 
98 % 
1.425-1.431 
0.830-0.836 
02.131 
 
But-3-en-2-ol   6) 
 
 
 
598-32-3 
Liquid 
C4H8O 
72.11 
Slightly soluble 
Freely soluble 
90 
 
MS 
95 % 
1.409-1.415 
0.831-0.837 
02.136 
1153 
Dec-1-en-3-ol   6) 
 
3824 
 
51100-54-0 
Liquid 
C10H20O 
156.27 
Slightly soluble 
Miscible 
215 
 
NMR MS 
97 % 
1.439-1.446 
0.836-0.842 
02.155 
1842 
1-Hepten-3-ol   6) 
 
4129 
10218 
4938-52-7 
Liquid 
C7H14O 
114.19 
Practically insoluble or 
insoluble 
Freely soluble 
155 
 
MS 
97 % 
1.431-1.437 
0.834-0.837 
02.187 
 
Non-1-en-3-ol   6) 
 
 
10291 
21964-44-3 
Liquid 
C9H18O 
142.24 
Practically insoluble or 
insoluble 
Freely soluble 
195 
 
MS 
98 % 
1.438-1.444 
0.835-0.845 
OH
OH
OH
OH
OH
OH
OH
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Table 1:  Specification Summary of the Substances in the present group 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formul
a 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
4) 
Spec.gravity 5) 
07.081 
1148 
Oct-1-en-3-one 
 
3515 
2312 
4312-99-6 
Liquid 
C8H14O 
126.20 
Insoluble 
Miscible 
37-38 (3 hPa) 
 
NMR 
96 % 
1.428-1.439 
0.813-0.819 
07.102 
1147 
Pent-1-en-3-one 
 
3382 
11179 
1629-58-9 
Liquid 
C5H8O 
84.12 
Insoluble 
Miscible 
68-70 (260 hPa) 
 
NMR 
97 % 
1.417-1.422 
0.842-0.848 
07.161 
 
Hex-1-en-3-one 
 
 
 
1629-60-3 
Liquid 
C6H10O 
98.14 
Practically insoluble or 
insoluble 
Freely soluble 
128 
 
MS 
95 % 
1.420-1.426 
0.849-0.855 
07.210 
 
1-Nonene-3-one 
 
 
 
24415-26-7 
Liquid 
C9H16O 
140.22 
Insoluble 
Freely soluble 
80 (16 hPa) 
 
MS 
95 % 
1.436-1.442 
0.826-0.830 
09.281 
1836 
Oct-1-en-3-yl acetate   
6) 
 
3582 
11716 
2442-10-6 
Liquid 
C10H18O2 
170.25 
Practically insoluble or 
insoluble 
Freely soluble 
80 (2 hPa) 
 
NMR 
97 % 
1.418-1.428 
0.865-0.886 
09.282 
1837 
Oct-1-en-3-yl 
butyrate   6) 
 
3612 
 
16491-54-6 
Liquid 
C12H22O2 
198.32 
Practically insoluble or 
insoluble 
Freely soluble 
81 (0.46 hPa) 
 
IR NMR MS 
95 % 
1.418-1.428 
0.865-0.875 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95%  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
 
O
O
O
O
O
O
O
O
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Current Safety Evaluation Status Applying the Procedure (Based on the MSDI Approach) (JECFA, 2002c; JECFA, 2009c) 
Table 2:  Summary of Safety Evaluation of the JECFA substances in the present group 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
JECFA Outcome on 
the named 
compound [4) or 5)] 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
02.023 
1152 
Oct-1-en-3-ol 
 
240 
23 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required.  
02.099 
1150 
Pent-1-en-3-ol 
 
2.1 
1 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required.  
02.104 
1151 
Hex-1-en-3-ol 
 
0.55 
2 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required. 
02.136 
1153 
Dec-1-en-3-ol 
 
ND 
0.1 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required. 
02.155 
1842 
1-Hepten-3-ol 
 
0.13 
 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required.  
07.081 
1148 
Oct-1-en-3-one 
 
1.2 
0.1 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required. 
07.102 
1147 
Pent-1-en-3-one 
 
0.29 
0.1 
Class II 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required.  
02.131 
 
But-3-en-2-ol 
 
0.0012 
 
Class II 
No evaluation 
Not evaluated by the 
JECFA. 
Evaluated in FGE.205, 
additional genotoxicity 
data required. 
02.187 
 
Non-1-en-3-ol 
 
0.58 
 
Class II 
No evaluation 
Not evaluated by the 
JECFA. 
Evaluated in FGE.205, 
additional genotoxicity 
data required. 
07.161 
 
Hex-1-en-3-one 0.012 
 
Class II 
No evaluation 
Not evaluated by the 
JECFA. 
Evaluated in FGE.205, 
additional genotoxicity 
OH
OH
OH
OH
OH
O
O
OH
OH
O
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Table 2:  Summary of Safety Evaluation of the JECFA substances in the present group 
FL-no 
JECFA-
no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
JECFA Outcome on 
the named 
compound [4) or 5)] 
EFSA conclusion on the 
named compound 
(genotoxicity) 
 
data required. 
07.210 
 
1-Nonene-3-one 
 
0.0012 
 
Class II 
No evaluation 
Not evaluated by the 
JECFA. 
Evaluated in FGE.205, 
additional genotoxicity 
data required. 
09.281 
1836 
Oct-1-en-3-yl acetate 2.1 
 
Class I 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required.  
09.282 
1837 
Oct-1-en-3-yl 
butyrate 
0.0012 
 
Class I 
A3: Intake below 
threshold 
4) Evaluated in FGE.205, 
additional genotoxicity 
data required.  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND Not determined. 
O
O
O
O
O
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GENOTOXICITY (IN VITRO)  
Table 3:  Summary of Additionally submitted genotoxicity data on the representative substance of subgroup 1.2.2 
FL-no Chemical 
Name 
Test System in vitro  Test Object  Concentrations tested 
of Substance and Test 
Conditions  
Result  Reference  Comments  
[07.102] Pent-1-en-3-
one 
Reverse Mutation S. typhimurium 
TA100 
0 - 168.33 μg/plate*  
[1,4] 
Positive (Deininger et 
al., 1990) 
Highly toxic especially without S9. 
Mutagenicity observed with and without 
S9. Reduced mutagenicity with inhibition 
of monooxygenase, enhanced 
mutagenicity with addition of epoxide 
hydrolase.
Not reported Positive (Eder et al., 
1993) 
Assay conditions, doses and control 
revertants were not reported but same data 
as in Deininger et al, 1990.
SOS chromotest E.coli PQ37 0 - 5.05 μg* Positive (Deininger et 
al., 1990) 
Highly toxic. Positive in the presence of 
S9-mix (induction factor of 1.83). 
0 - 8.41 μg* Positive (Eder et al., 
1991a) 
Reported in graphical form for MVK 
only, but patterns were noted to be 
similar for EVK, previously published 
by Deininger (1990). 
0 - 8.41 μg* Positive (Eder et al., 
1993) 
DNA adducts E.coli PQ37 168 mg Positive (Eder et al., 
1993) 
1,N2-cyclic deoxyguanosine adducts 
and 7-linear guanine adducts were 
isolated. 
hprt assay Mouse lymphoma 
L5178Y cells 
0.1 - 1.2 μg/ml [3,9] 
0.5 - 5 μg/ml [5,9] 
0.1 - 1.2 μg/ml [3,10] 
2 - 7 μg/ml [5,9] 
0.25 - 1.1 μg/ml [3,10]  
 
Equivocal (Lloyd, 2011a) Highly toxic. Could only be tested in 
a narrow concentration range. Some 
indication of genotoxic effect at toxic 
concentrations, which was not 
reproducible. 
Micronucleus 
induction 
Human peripheral 
blood lymphocytes 
3.50 - 4.75 μg/ml [3,6], 
8 - 16 μg/ml [5,6], 
3 - 4 μg/ml [3,7] 
Negative (Lloyd, 2010b) Highly toxic. Could only be tested in 
a narrow concentration range. Some 
indication of genotoxic effect at toxic 
concentrations, which was not 
reproducible. 
[07.081] Oct-1-en-3-
one 
Reverse Mutation S. typhimurium 
TA98, TA100, 
0.32 - 1000 μg/plate [1] Positive (Beevers, 
2009c) 
All strains were negative, except TA100, 
with S9-mix treatment. 200 μg/plate 
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Table 3:  Summary of Additionally submitted genotoxicity data on the representative substance of subgroup 1.2.2 
FL-no Chemical 
Name 
Test System in vitro  Test Object  Concentrations tested 
of Substance and Test 
Conditions  
Result  Reference  Comments  
TA1535, TA1537 
and TA102 
resulted in 4.6-fold increase in revertants. 
Toxicity was observed at 1000 μg/plate. 
S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
and TA102 
15.6 - 500 μg/plate [2,3,8]  Negative All strains were negative, except that 
TA100 showed a slight 1.4-fold increase 
in revertants at the highest nontoxic 
concentration of 125 μg/plate without S9-
mix treatment and a 1.2-fold increase with 
S9-mix at 31.25 μg/plate. Both effects 
were significant but not biologically 
relevant (2-fold over control levels). All 
results from pre-incubation cohort were 
negative.
S. typhimurium 
TA100 
50 - 500 μg/plate [2,5] Negative 
S. typhimurium 
TA100 
100 - 300 μg/plate [1,2],  
15 - 120 μg/plate [5,8] 
Postive The plate incorporation method resulted in 
increased revertants by 2.3 to 3-fold with 
a 125 - 200 μg/plate treatment in the 
absence of S9-mix and 2.2 to 2.9-fold 
with a 100 - 200 μg/plate treatment in the 
presence of S9-mix, neither being dose 
dependent. The only pre-incubation 
treatment that resulted in increased 
revertants was 45 μg/plate treatments in 
the presence of S9-mix (1.7-fold). 
hprt assay Mouse lymphoma 
L5178Y cells 
0.05 - 2.5 μg/ml [3,9],  
0.5 - 7.5 μg/ml [5,9] 
0.5 - 3 μg/ml [3,9] 
0.5 - 4,5 μg/ml [5,9] 
0.1 - 2.5 μg/ml [3,10] 
Negative (Lloyd, 2011c) Highly toxic. Could only be tested in 
a narrow concentration range. Some 
indication of genotoxic effect at toxic 
concentrations, which was not 
reproducible. 
Micronucleus 
induction 
Human peripheral 
blood lymphocytes 
2 - 20 μg/ml [3,6], 
5 - 40 μg/ml [5,6]  
2 - 20 μg/ml [3,10] 
Negative (Lloyd, 2011b) Highly toxic. Could only be tested in 
a narrow concentration range. Some 
indication of genotoxic effect at toxic 
concentrations, which was not 
reproducible. 
* Values were converted from reported μM or nM concentrations to μg values. 
[1] With and without S9 metabolic activation. 
[2] Plate incorporation method. 
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[3] Without S9 metabolic activation. 
[4] Pre-incubation method. 
[5] With S9 metabolic activation. 
[6] 3-hour incubation with 21-hour recovery period. 
[7] 24-hour incubation with no recovery period. 
[8] Pre-incubation method with S9 metabolic activation. 
[9] 3-hour treatment. 
[10] 24-hour treatment. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
DMSO  Dimethyl Sulphoxide 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EU  European Union 
EVK  Ethyl Vinyl Ketone 
FAO  Food and Agriculture Organization of the United Nations  
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
HPRT  Hypoxanthine-guanine phosphoribosyl transferase 
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MVK  Mehyl Vinyl Ketone 
MF  Mutant frequency 
MNBN  MicroNucleated BiNucleate cells 
MS  Masse spectra 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NMR  Nuclear Magnetic Resonance 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
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PHA  Phytohaemagglutinin 
(Q)SAR (Quantitative ) Structure Activity Relationship 
RI  Replication index 
RS  Relative survival 
SCF  Scientific Committee on Food 
SKF  2'-Diethylaminoethyl 2,2-diphenylpentanoate hydrochloride 
SOSIP  SOS inducing potency 
WHO  World Health Organisation 
